Researchers are looking for participants to test a potential new treatment for OCD
Volunteers taking part will be reimbursed for their time (including reasonable travel costs) and may be offered the study medication free of charge for 48 weeks.
A leading clinical research organisation is running a clinical trial to test a potential new medication for people living with OCD.
According to the NHS, it is estimated that a quarter of a million people are living with OCD in the UK at some point in their lives, that’s equivalent to 12 in every 1,000.
This number increases drastically when we consider those who haven’t received a diagnosis who could be living with OCD symptoms and not receiving the professional support they may need or understand why they are experiencing intrusive thoughts.
Dr Alex Worthington, Clinical Research Physician at MAC Clinical Research, explains that “obsessive-compulsive disorder, commonly referred to as OCD, is a mental health condition with three main parts: obsessions, emotions, and compulsions.
For #OCDWeek, we wanted to highlight some statistics and information to raise awareness of #OCD.
If you have OCD and are having little to no response to your current antidepressant treatment, you may be eligible to take part in a clinical trial.
“Obsessions are persistent thoughts, images, doubts, worries, or urges that intrude on an individual’s mind, despite being unwanted.
ADVERTISEMENT
“These thoughts can cause significant mental discomfort or anxiety. Some of the emotions felt due to intrusive thoughts can include guilt, depression, and disgust.
“Compulsions refer to repetitive behaviours that an individual engages in to temporarily alleviate the anxiety caused by the obsession. Examples of compulsions include checking if a door is locked multiple times or repeating certain phrases mentally.”
ADVERTISEMENT
There’s a need for more effective treatment options for OCD, which is why award-winning clinical research organisation, MAC Clinical Research is conducting a clinical trial to test a potential new treatment that is hoped to reduce OCD symptoms and ultimately improve quality of life.
Here at MAC, our OCD clinical trial is open for people struggling with OCD symptoms.
Eligible participants will receive up to £490 plus reasonable travel expenses.
If you or someone you know has been living with OCD or OCD symptoms, and provided you meet the overall criteria, you could be reimbursed up to £490 for your time and participation in the clinical trial plus reasonable travel expenses.
If the treatment works, you may be able to receive nearly a year’s worth (48 weeks) of the medication free of charge as part of an open-label extension study.
ADVERTISEMENT
You can find out more and register your interest HERE.
As explained in the summary for this clinical trial, “people with OCD tend to have signalling pathways in the brain which are overactive, causing intrusive thoughts, compulsive behaviour or other OCD symptoms.
“Previous clinical trials suggest that the study medication works to dampen down these overactive pathways which may help people with OCD when used in combination with their usual antidepressant medication.”
The study is expected to run for approximately five months. The trial itself will involve taking the oral medication or a placebo daily for ten weeks alongside seven visits to the clinic for check-ups to examine if your OCD symptoms improve and how well you are coping with taking the medication.
As part of International OCD Awareness Week, MAC also looked intohow the condition affects people in the workplace and answered some of the public’s pressing questions surrounding the disorder with one of the organisation’s leading psychiatrists, Dr David Gregory.
ADVERTISEMENT
One of MAC’s leading psychiatrists sheds light on OCD treatment.
To ensure optimal safety, each study participant must meet a pre-determined set of eligibility criteria. To be eligible for the trial, you need to:
Be aged between 18-65
Have had OCD symptoms or an OCD diagnosis for at least 1 year that affects daily life.
Be taking an antidepressant for your OCD that isn’t fully helping.
To ensure optimal patient safety, participants must not have any of the following:
Bipolar, schizophrenia, autism, Tourette’s, or other psychiatric conditions
Diagnosed with an eating disorder.
Have diabetes that requires insulin.
Other criteria will apply.
If you want to learn more about MAC Clinical Research or if you’re considering being part of the clinical trial, you can learn more and register your interest by visiting their OCD research webpage.
For #OCDWeek, we wanted to share what some of our clinical trial participants said made them want to take part in OCD clinical research with MAC.
Featured Image — MAC Clinical Trial/The Manc Group
Sponsored
Manchester’s new aesthetics clinic with a budget-friendly tiered pricing model
The Manc
There’s a new medically–led aesthetics clinic in the heart of Manchester, which offers a tiered pricing model that will get you the right treatment at a price that suits your budget.
The Academy Clinic has opened up on Quay Street, specialising in natural, balanced results with a massive range of injectable and cosmetic dermatology treatments
The clinic was founded by Dr Tristan Mehta, Dr Emily Mehta, and Dr Marcus Mehta, who want to raise the standards of injectable and cosmetic dermatology treatments across the UK.
It’s part of Harley Academy, the UK’s leading provider of postgraduate training in aesthetic medicine.
And that’s what sets it apart from a lot of other clinics in the UK, and makes it a stand-out in an industry that is largely unregulated – at The Academy Clinic you won’t ever be treated by non-medics or anyone without formal medical training.
It means that you are always in the hands of a registered medical professional – whether it be practitioner or trainee, and doctor, nurse, dentist or clinical pharmacist – who would be able to manage complications, so you can feel confident you’re in the best hands.
The Academy Clinic in Manchester. Credit: Supplied
And the tiered treatment model really does suit every patient’s budget and preferences – you can take a more affordable treatment option, where qualified medical professionals are learning and being upskilled with expert supervision during your treatment; or you can opt for a fully private experience with a senior practitioner and no training elements involved.
There’s a wide range of treatments available, including popular injectable skin treatments such as Profhilo® and Profhilo Structura®, polynucleotides, dermal fillers, microneedling, HydraFacial and more, all designed to deliver natural-looking, confidence-boosting results.
Beyond patient care, The Academy Clinic’s clinical team also trains and mentors medical professionals through its GMC-registered aesthetics training academy, Harley Academy.
Dr Tristan Mehta, Founder & CEO of The Academy Clinic and Harley Academy, said: “Our mission has always been to raise standards in aesthetics. By combining education with patient care, we can ensure treatments are delivered safely, ethically, and with natural results.
Treatments include HydraFacials
“Bringing The Academy Clinic to Manchester means more people can access medically-led aesthetics with confidence.”
The Academy Clinic is now open at St John’s Court on Quay Street in Manchester, having acquired SkinViva last October.
To keep up to date with the latest news and promotions, you can follow The Academy Clinic on Instagram @theacademyclinic. For bookings or enquiries, call 0161 865 1141, visit theacademyclinic.co.uk or email [email protected].
Exclusive offer for The Manc readers: Use code MANC25 at the time of booking or when in clinic for 25% off any treatments excluding wrinkle reduction treatments.
Wigan favourites Stanleys release first single ahead of debut album next year
Danny Jones
Fast-rising Wigan band Stanleys have dropped the lead single from their debut album, which is finally on its way and will be coming sometime next year.
Entitled ‘Pass The Time’, the Stanleys’ latest outing arrived on Friday, 20 February, and while there’s still no specific release date for the first-ever full-length LP, we do know it’s coming at some point in 2027.
To simply label it as more catchy indie would be a disservice to the craft and graft these lads have put in: this is definitely a step forward and in a slightly different direction, with an even more guitar-driven feel and an extra bit of gruff about it compared to previous Stanleys material.
Our only minor complaint is that we wish it lasted a little longer – we want MORE.
An energetic two-and-a-half-minute track that we can already see becoming a fan favourite, it’s one we’re looking forward to hearing in the flesh.
We’ve caught the Stanleys boys live a few times now, both here in Manchester city centre and at their sold-out show in Wigan as part of The Monaco relaunch, as well as at the likes of Kendal Calling festival in recent years.
Safe to say, they never disappoint, and neither do their growing crowd of die-hards.
With lyrics touching on not just the passing of time but also that sense of youthful ambition and how it fluctuates with age, it feels like one of those defiant indie rallying cries we grew up listening to in our own adolescence, and it definitely has plenty of energy to it.
Both The Manc and our wider Audio North team had the pleasure of chatting with them back in November 2024, and you can tell they have big plans to take on not just the local music scene but the UK and beyond.
The release of ‘Pass The Time’ comes almost a year on from their last song, ‘Out the Door’: a similarly fast-run song, albeit with a different vibe.
Positioned as part of Wigan’s next generation of new bands and artists, Stanleys are clearly looking to keep developing as musicians, and if tunes like these are anything to go by, then we can’t wait for their first full record.
They’re also going to be playing a night here in Manchester city centre and beloved grassroots venue, Night and Day, this April; you can grab tickets HERE.
So get adding it to your Spotify playlists, watching the music video, and maybe we’ll see you at the gig.